Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA.

Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19.

PMID:
30089591
2.

Lung cancer in never smokers from the Princess Margaret Cancer Centre.

Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA.

Oncotarget. 2018 Apr 27;9(32):22559-22570. doi: 10.18632/oncotarget.25176. eCollection 2018 Apr 27.

3.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
4.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Sep;17(3):231-239.e7. doi: 10.1016/j.clcc.2018.03.001. Epub 2018 Mar 8.

PMID:
29653857
5.

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24.

PMID:
28838393
6.

Is chemotherapy always required for cancer in pregnancy? An observational study.

Walsh EM, O'Kane GM, Cadoo KA, Graham DM, Korpanty GJ, Power DG, Carney DN.

Ir J Med Sci. 2017 Nov;186(4):875-881. doi: 10.1007/s11845-017-1602-3. Epub 2017 May 5.

PMID:
28477329
7.

Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.

Korpanty GJ, Eng L, Qiu X, Faluyi OO, Renouf DJ, Cheng D, Patel D, Chen Z, Tse BC, Knox JJ, Dodbiba L, Teichman J, Azad AK, Wong R, Darling G, Reisman D, Cuffe S, Liu G, Xu W.

Oncotarget. 2017 Apr 25;8(17):28093-28100. doi: 10.18632/oncotarget.15890.

8.

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.

Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA.

Radiother Oncol. 2017 May;123(2):195-202. doi: 10.1016/j.radonc.2017.03.007. Epub 2017 Mar 28.

PMID:
28363487
9.

ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.

Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, Dudnik E, Peled N, Shochat T, Leighl NB, Liu G, Feld R, Burkes R, Wollner M, Tsao MS, Shepherd FA.

Clin Lung Cancer. 2017 Mar;18(2):156-161. doi: 10.1016/j.cllc.2016.10.007. Epub 2016 Oct 26.

PMID:
27913214
10.

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.

Korpanty GJ, Graham DM, Vincent MD, Leighl NB.

Front Oncol. 2014 Aug 11;4:204. doi: 10.3389/fonc.2014.00204. eCollection 2014. Review.

11.

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT.

Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31.

12.

Bronchoesophageal fistula in a patient with stage IIIB non-small-cell lung cancer.

Korpanty G, Alken S, Smyth L, Greene J, El-Helali A, Grogan L, Breathnach OS.

J Thorac Oncol. 2012 Oct;7(10):1622. doi: 10.1097/JTO.0b013e3182606a4c. No abstract available.

13.
14.

Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?

Korpanty G, Smyth E, Carney DN.

J Thorac Dis. 2011 Mar;3(1):19-29. doi: 10.3978/j.issn.2072-1439.2010.11.11.

15.

Complete radiological response of metastatic anaplastic lymphoma kinase-positive signet ring lung adenocarcinoma to systemic chemotherapy.

Korpanty G, Mulligan N, Carney DN.

J Thorac Oncol. 2011 May;6(5):963-5. doi: 10.1097/JTO.0b013e318215a242. No abstract available.

16.

Phyllodes tumor of the breast.

Korpanty G, Power DG, Murphy C, Kell M, McCaffrey J.

Med Oncol. 2011 Dec;28 Suppl 1:S62-4. doi: 10.1007/s12032-010-9695-9. Epub 2010 Oct 2.

PMID:
20890734
17.

Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA.

J Oncol. 2010;2010:652320. doi: 10.1155/2010/652320. Epub 2010 Jun 10.

18.

Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.

Korpanty G, Smyth E, Sullivan LA, Brekken RA, Carney DN.

Exp Biol Med (Maywood). 2010 Jan;235(1):3-9. doi: 10.1258/ebm.2009.009191. Review.

19.

Small-cell carcinoma of the cervix at 23 weeks gestation.

Smyth EC, Korpanty G, McCaffrey JA, Mulligan N, Carney DN.

J Clin Oncol. 2010 Jun 20;28(18):e295-7. doi: 10.1200/JCO.2009.25.5604. Epub 2010 Apr 12. No abstract available.

PMID:
20385993
20.

Loss of fibulin-5 binding to beta1 integrins inhibits tumor growth by increasing the level of ROS.

Schluterman MK, Chapman SL, Korpanty G, Ozumi K, Fukai T, Yanagisawa H, Brekken RA.

Dis Model Mech. 2010 May-Jun;3(5-6):333-42. doi: 10.1242/dmm.003707. Epub 2010 Mar 2.

21.

Primary bone lymphoma: single institution case series.

Power DG, McVey GP, Korpanty G, Treacy A, Dervan P, O'Keane C, Carney DN.

Ir J Med Sci. 2008 Sep;177(3):247-51. doi: 10.1007/s11845-008-0165-8. Epub 2008 May 31.

PMID:
18516662
22.

Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC.

Arnold S, Mira E, Muneer S, Korpanty G, Beck AW, Holloway SE, Mañes S, Brekken RA.

Exp Biol Med (Maywood). 2008 Jul;233(7):860-73. doi: 10.3181/0801-RM-12. Epub 2008 Apr 29.

23.

Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.

Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA.

Clin Cancer Res. 2007 Jan 1;13(1):323-30.

24.

Targeting vascular endothelium with avidin microbubbles.

Korpanty G, Grayburn PA, Shohet RV, Brekken RA.

Ultrasound Med Biol. 2005 Sep;31(9):1279-83.

PMID:
16176794
25.

Targeting of VEGF-mediated angiogenesis to rat myocardium using ultrasonic destruction of microbubbles.

Korpanty G, Chen S, Shohet RV, Ding J, Yang B, Frenkel PA, Grayburn PA.

Gene Ther. 2005 Sep;12(17):1305-12.

PMID:
15829992
26.

[The influence of histamine and second generation of antihistamine drugs on cardiovascular system].

Adamek-Guzik T, Korpanty G, Guzik T, Czerniawska-Mysik G.

Pol Arch Med Wewn. 2002 Aug;108(2):785-95. Review. Polish. No abstract available.

PMID:
12476899
27.

Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermatitis syndrome. Relation to clinical status.

Adamek-Guzik T, Guzik TJ, Czerniawska-Mysik G, Korpanty G, Mastalerz L, Radwan J, Szczeklik A.

Allergy. 2002 Aug;57(8):732-6.

28.

[Self-estimation of the quality of life in adult patients after surgical correction of atrial septal defect type II (ASD II)].

Konstanty J, Guzik B, Maleta P, Korpanty G, Pfitzner R.

Przegl Lek. 2001;58(9):851-4. Polish.

PMID:
11868246
29.

Supplemental Content

Loading ...
Support Center